Innovative Automated Insulin Delivery System for Type 2 Diabetes
NCT ID: NCT06853990
Last Updated: 2026-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
300 participants
INTERVENTIONAL
2025-04-14
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)
NCT05823948
Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes
NCT00698802
A 2-Month Safety Follow-Up Trial
NCT00741429
To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus.
NCT00419302
A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382
NCT03341013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
twiist users
twiist insulin delivery system
twiist system includes a novel insulin pump, a CGM sensor and the DEKA Loop algorithm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
twiist insulin delivery system
twiist system includes a novel insulin pump, a CGM sensor and the DEKA Loop algorithm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Clinical diagnosis of type 2 diabetes based on investigator assessment of at least 6 months duration at time of screening.
3. Using one of the following insulin regimens for at least 13 weeks prior to screening: (1) basal-bolus insulin therapy with at least one injection containing rapid-acting insulin per day, (2) open-loop insulin pump, (3) premixed insulin with a rapid component, (4) basal insulin without bolus insulin.
4. If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that can have a meaningful effect on glycemia, dose has been stable for at least 4 weeks prior to screening in the judgement of the investigator, and there are no plans to change the dose during the duration of the study. If not using glucose-lowering or weight-reduction medications that can have a meaningful effect on glycemia, participant agrees to not initiate such medications during the duration of the study.
5. Willing and able to use only insulin approved for use in the study pump.
6. Has the ability to read and understand written English or another language available as an option for the pump's user interface.
7. Investigator believes that the participant has the cognitive capacity to provide informed consent.
8. Investigator believes that the participant can successfully and safely operate all study devices and is capable of adhering to the protocol and completing the study.
a. This includes considering the potential impact of medical conditions known to be present including cardiovascular, liver, kidney disease, thyroid disease, adrenal disease, malignancies, vision difficulties, active proliferative retinopathy, and other medical conditions; psychiatric conditions including eating disorders; drug or alcohol abuse.
9. Willing to participate in the study meal and exercise challenges and have a care partner willing to be trained in hypoglycemia treatment guidelines present during and immediately after the exercise challenges (not required if exercise sessions will be done in clinic).
10. Participants capable of becoming pregnant must meet one of the following criteria:
a. Has a negative urine pregnancy test and agrees to use one of the accepted contraceptive regimens throughout the entire duration of the trial from screening until last follow-up visit. The following contraceptive measures are considered adequate: i. Combined estrogen and progesterone containing hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal).
ii. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable).
iii. Placement of an intrauterine device or intrauterine hormone-releasing system.
iv. Bilateral tubal occlusion. v. Barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository).
vi. Has a vasectomized or sterile partner (where partner is sole partner of subject) and where vasectomy has been confirmed by medical assessment.
vii. Exercises true sexual abstinence. Sexual abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.
or b. Participant is of non-childbearing potential due to menopause with at least one year since last menses or a medical condition confirmed by the investigator.
Exclusion Criteria
2. Use of an FDA-approved or non-FDA approved closed-loop or hybrid closed-loop insulin delivery system within the past 3 months.
3. Pregnancy (as demonstrated by a positive test) or breast-feeding at time of screening or planning to become pregnant during the next 4 months.
4. Concomitant disease or condition that in the opinion of the investigator may compromise patient safety including but not limited to; cystic fibrosis, severe mental illness, a diagnosed or suspected eating disorder or any uncontrolled long term medical condition that would interfere with study related tasks or visits.
5. Current use of implantable CGM sensor (e.g., Senseonics)
6. Current use of at least 500 mg of ascorbic acid (Vitamin C)
7. Presence of a hemoglobinopathy or other condition that is expected to affect the measurement of HbA1c in the judgment of the investigator.
8. Immediate family member (spouse, child, sibling, parent) of any person at an investigative site who is directly affiliated with this study or who is an employee of Sequel Med Tech, Millyard Advanced Medical Products LLC, Merrimack Manufacturing, or DEKA Research and Development Corp.
9. More than 2 severe hypoglycemic events requiring third party help or hospitalization within the last 6 months prior to screening
10. More than one DKA or HHS event within the last 6 months prior to screening
11. Lack of reliable telephone or internet service (for contact)
12. Known allergy to medical grade adhesives or skin condition that precludes use of the study pump or CGM
13. Current participation in another diabetes-related interventional clinical trial.
14. Anticipated change of residency or travel for more than 14 days at a time during the study that may, per investigator judgment, interfere with the completion of study visits, contacts, or procedures.
15. Feasibility Phase only: Clarke Hypoglycemia Awareness Survey score of 4 or greater.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sequel Med Tech
UNKNOWN
Deka Research and Development
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scripps Whittier Diabetes Institute
La Jolla, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Sansum Diabetes Research Institute
Santa Barbara, California, United States
University of Colorado
Aurora, Colorado, United States
University of Miami
Miami, Florida, United States
Emory University
Atlanta, Georgia, United States
Endocrine Research Solutions, Inc
Roswell, Georgia, United States
Rocky Mountain Clinical Research, LLC
Idaho Falls, Idaho, United States
Endeavor Health
Skokie, Illinois, United States
IU Health University Hospital
Indianapolis, Indiana, United States
Iowa Diabetes & Endocrinology Research Center
West Des Moines, Iowa, United States
University of Maryland
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Boston Medical Center
Boston, Massachusetts, United States
Joslin Diabetes Center
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Henry Ford Health
Detroit, Michigan, United States
International Diabetes Center - Health Partners Institute
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Naomi Berrie Diabetes Center
New York, New York, United States
SUNY Upstate Medical University
Syracuse, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
University Diabetes & Endocrine Consultants
Chattanooga, Tennessee, United States
Texas Diabetes & Endocrinology, P.A.
Austin, Texas, United States
Diabetes & Endocrine Treatment Specialists
Sandy City, Utah, United States
University of Washington
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DKPI-00730-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.